Gala is a direct-to-consumer telehealth platform providing compounded GLP-1 and GIP (Tirzepatide) medications. They are currently the most competitive provider in the US market, offering monthly plans starting at $179 for all dosages, which includes the physician consultation and prescription.

Converts on Subscription Purchase.

Targeting: Primarily women (70% of the core audience) aged 27–60. Focus on budget-conscious weight loss seekers who are frustrated by the high cost or "out-of-stock" status of brand-name Ozempic or Mounjaro. The $179 price point is the strongest hook for those looking for the cheapest legal access to compounded Tirzepatide.

Restrictions: Strict FTC Compliance. No misleading claims, fake doctor endorsements, or unauthorized "before and after" photos. You must not claim these are "generic" versions of brand-name drugs; they must be referred to as "compounded." No brand bidding on pharmaceutical trademarks.